Budget impact analysis of glecaprevir/pibrentasvir treatment for hepatitis C in Iran: a modelling study

Introduction

Hepatitis C virus (HCV), with a 3% prevalence rate,1 is recognised as a public health problem worldwide.2 Hepatitis C imposes a significant economic burden on households and society.3 4 For example, the economic burden of chronic hepatitis C (CHC) in the United States alone is greater than $10 billion annually.4

In Iran, the prevalence of hepatitis C is between 0.1% and 0.3% and has been on an upward trend in recent years.5–7 Additionally, the total direct cost of treating hepatitis C is anticipated to be higher than household consumption expenditure. This emphasises the need for planning and insurance coverage, especially for expensive new medications, to reduce the household cost.8

In recent years, newly introduced direct-acting antiviral drugs have shown significant efficacy and safety for treating hepatitis C.9 10 The costs of these novel treatment methods are greater than those of previous methods and include a significant portion of the economic burden of hepatitis C.11 12

Sofosbuvir/daclatasvir (SOF/DCV) and sofosbuvir/velpatasvir (SOF/VEL) are two cost-effective treatment methods for the treatment of hepatitis C used in Iran.13 14 Moreover, glecaprevir/pibrentasvir (GLE/PIB), despite its high costs, has been recognised as one of the most effective medications for hepatitis C, which can enhance the quality of life and reduce the mortality rate of patients in some countries.10 15 GLE/PIB has not yet been added to Iran’s official drug list. Additionally, there has been no study that evaluates the effect of GLE/PIB’s entry into Iran’s drug list from a health policy perspective, estimating the budgetary changes in the pharmaceutical market and the entire health sector after the drug’s entry. Budget impact analysis,16 as part of a comprehensive economic assessment that is used in most developed countries for budget planning, can provide a clear picture of the effect of the new technology or treatment method on the budget of the entire health system to predict the need for necessary allocation of resources.17 Therefore, this study aimed to analyse the budgetary impact of the entry of GLE/PIB into Iran’s drug list to equip policymakers with documented results and provide a helpful tool for financing, resource allocation and insurance reimbursement for patients with hepatitis C.

Results

Population and target patients

The population of patients with hepatitis C and those using SOF/DCV and SOF/VEL medications over the next 5 years has been estimated, considering population growth, incidence and prevalence rates, as shown in table 1.

Table 1

Estimated population of patients with hepatitis C in the next 5 years in Iran using the patient map

A general overview of the proportion of potential users for the new medication option in the entry scenario (scenario 1) and the non-entry scenario (scenario 2) of the GLE/PIB in Iran’s drug list is shown in online supplemental table 11.

Costs

The average treatment cost of one patient with hepatitis C based on one treatment cycle in terms of medication cost and based on 1-year treatment cost in terms of the direct medical costs of the treatment for all three medication options, SOF/DCV, SOF/VEL and GLE/PIB, is presented in online supplemental table 8.

Budget impact analysis on the health system

The impact of the introduction of a new drug in Iran’s drug list on the health sector budget is presented in table 2 and figure 2. All direct medical costs, including medication costs in all three treatment strategies, office visit costs, laboratory services, radiology examinations, diagnostic tests, hospitalisations and other direct medical costs, are considered in the budget impact analysis on the health system. As illustrated, by assuming that GLE/PIB will capture 10%, 20%, 30%, 40% and 50% of the market share of hepatitis C in the next 5 years, the health sector budget will increase by approximately $0.61, $1.77, $3.86, $7.45 and $13.51 million in the first to fifth year, respectively.

Table 2

The health sector’s budgetary changes over the next 5 years in Iran, with or without the entry of GLE/PIB

Figure 2
Figure 2

Impact of the introduction of a new drug on Iran’s health sector budget.

Budget impact analysis on the pharmaceutical market

The budget impact of GLE/PIB introduction on the pharmaceutical market is shown in table 3. Over the next 5 years, the hepatitis C market is expected to experience a 468% budget increase in the pharmaceutical market, which will account for 0.13% of the total sales of Iran’s pharmaceutical market.

Table 3

Iran’s pharmaceutical market budgetary changes over the next 5 years with or without GLE/PIB entry

According to the budget impact analysis, the total number of 300/60 mg GLE/PIB tablets that patients will consume in the coming years is presented in table 4.

Table 4

Total GLE/PIB 300/60 mg doses needed in Iran’s pharmaceutical market for the next 5 years

Sensitivity analysis

The results of the one-way sensitivity analysis and Tornado diagrams (figures 3 and 4) indicate that the model outcomes are sensitive to changes in the cost associated with the CHC state for all three medications. Additionally, fluctuations in the prices of the drugs also affect the CHC state costs.

Figure 3
Figure 3

Tornado diagram: comparison of the incremental cost between GLE/PIB vs SOF/DCV. CHC, chronic hepatitis C; GLE/PIB, glecaprevir/pibrentasvir; SOF/DCV, sofosbuvir/daclatasvir

Figure 4
Figure 4

Tornado diagram: comparison of the incremental cost between GLE/PIB vs SOF/VEL. CHC, chronic hepatitis C; GLE/PIB, glecaprevir/pibrentasvir; SOF/VEL, sofosbuvir/velpatasvir

The price sensitivity analysis demonstrated that a simultaneous 20% increase or decrease in the price of all three medications does not affect the percentage of budget changes in the pharmaceutical market. Consequently, the introduction of a new drug is projected to result in a 468% increase in the pharmaceutical market budget over the next 5 years.

Regarding total health sector costs, a 20% reduction in CHC state costs over 5 years would decrease the overall increase in health sector costs from $13.51 million (an 18.84% increase) to $10.52 million (an 18.16% increase). Conversely, a 20% rise in CHC state costs would increase the health sector costs from $13.51 million (an 18.84% increase) to $16.49 million (a 19.31% increase).

Additionally, PSA was conducted using 5000 Monte Carlo simulations to account for uncertainty in the input parameters. As summarised in Appendix Table 19, the estimated mean annual treatment costs are $5461 for SOF/VEL, $7500 for GLE/PIB and $5465 for SOF/DCV. The associated 95% CIs were narrow: $5438–$5483, $7484–$7515 and $5453–$5478, respectively, indicating consistent cost estimates under parameter variability.

Discussion

HCV infection22 continues to be a significant public health concern in the Middle East and North Africa (MENA), particularly in low-income and middle-income countries, which bear a higher burden than high-income nations.33–35 In 2015, the overall prevalence rate in MENA was 0.64%, translating to approximately 2.0 million viremic infections. However, prevalence rates vary considerably by country, ranging from 0.2% in Iran, Iraq and Lebanon to 3.0% in Syria.36 37

In Iran, the overall prevalence is lower than the global average, yet specific high-risk groups, such as individuals who use injectable drugs, present critical public health challenges. Limited access to diagnostics and antiviral treatments—due to high costs and inadequate healthcare infrastructure—complicates efforts to control hepatitis C in developing countries.1 7 33 Since 1997, screening donated blood for hepatitis C has helped reduce the number of cases, and providing free treatment for diagnosed patients has improved overall management. Nonetheless, the effectiveness of screening and testing programmes remains crucial for increasing access to treatment in various communities across the region. This highlights the urgent need for enhanced healthcare policies that address the specific needs of this population.7 This study’s findings provide practical insights into the costs of effective drug treatment and its implications for healthcare budgets in Iran, ultimately contributing to efforts to control and eliminate hepatitis C.

Currently, in Iran, two primary medications are available for the management of patients with hepatitis C: SOF/DVC and SOF/VEL. According to the drug sale statistics from Iran’s ‘Amarnameh’,21 the economic implications of hepatitis C treatment are significant for households, with the sales of these two medications reaching $31 102 295 in 2021, followed by $22 718 468 in 2022 and a slight increase to $23 803 251 in 2023. In addition to these options, GLE/PIB is considered a particularly promising treatment for hepatitis C. Clinical evidence suggests that GLE/PIB shows superior efficacy to both SOF/VEL and SOF/DVC, making it a compelling choice for patients. Furthermore, GLE/PIB is recognised for its cost-effectiveness, presenting a valuable intervention in the management of hepatitis C. With its added benefits, GLE/PIB can significantly penetrate the hepatitis C market, potentially capturing 50% of the market share within the next 5 years. Therefore, given the presence of a population at risk of hepatitis C and the availability of effective treatment options for managing these patients, the need to focus on planning and insurance coverage for these costly drug therapies, to reduce household expenses, is more evident than ever.

Budget impact analysis is a crucial tool for policymakers and health planners to assess the costs and financial implications of introducing new treatments or modifying treatment policies. In Iran’s healthcare system, where Iran’s Ministry of Health has adopted policies to provide free management for patients, the importance of using this tool for informed decision-making and allocating necessary budgets has become more significant than ever. The adoption of policies for managing patients with hepatitis C, such as free treatment policies for this population, underscores the need for precise financial planning. By conducting budget impact analysis, policymakers can better understand the short-term and long-term economic consequences of these initiatives. This tool enables them to assess whether the allocated resources are sufficient to cover the costs of widespread treatment and identify potential gaps in funding.

In this study, the budgetary changes within the healthcare system and the costs of the pharmaceutical market were analysed based on the direct expenses related to treating a single patient. This analysis is based on standard management practices for hepatitis C within Iran’s health system, along with the total number of patients diagnosed with hepatitis C. The study findings show that the first scenario, entry of GLE/PIB into Iran’s drug list and health system, considering the high cost of new medication, increases the total cost of Iran’s pharmaceutical market and health system, compared with the second scenario, non-entry of GLE/PIB into Iran’s drug list and management of patients with available options. By considering the direct costs of treatment, including medication costs, office visits, laboratory services, radiology examinations, diagnostic tests, hospitalisation and other direct medical costs, with the introduction of GLE/PIB and assuming that new medication will reach 10%, 20%, 30%, 40% and 50% market share from first to fifth year, the healthcare system costs will increase by approximately $0.61, $1.77, $3.86, $7.45 and $13.5 million over the next 5 years, respectively. However, a study conducted in Malaysia in 2023 found that the introduction of SOF/VEL for the treatment of hepatitis C resulted in $1.4 million, equivalent to a 0.57% decrease in cumulative total healthcare costs over 5 years, compared with SOF/DCV. It was mainly due to the shorter treatment course of SOF/VEL compared with SOF/DCV.18 The increased treatment costs for GLE/PIB in Iran, compared with the cost savings from SOF/VEL in Malaysia, can likely be attributed to the fact that GLE/PIB is five times more expensive than SOF/VEL and 13 times more expensive than SOF/DCV. This high cost is primarily due to the availability of domestically produced alternatives for the other medications.

Additionally, based on the selling prices of all three medication options, GLE/PIB, SOF/VEL and SOF/DCV, there will be a 468% rise in Iran’s pharmaceutical market costs, which is equivalent to a 0.13% increase in the total market costs. Additionally, with the assumed 50% market share on the introduction of GLE/PIB into Iran’s healthcare system, there will be a need for 65 602 GLE/PIB tablets in the fifth year. This result aligns with a 2015 study conducted in the United States that examined the budget impact of sofosbuvir/ledipasvir for treating hepatitis C. The findings indicate that the introduction of sofosbuvir/ledipasvir could lead to a $65 billion increase in medication costs compared with the standard of care. However, this approach would only provide a cost offset of $16 billion, which accounts for just 24% of the additional treatment expenses. This suggests that while the new treatment option may be cost-effective for patients, the overall increase in medication costs outweighs the reductions in other treatment expenses, resulting in a greater economic burden on the healthcare system.9

Furthermore, based on the gap between the number of patients with hepatitis C and the number of patients who are receiving treatment in Iran, there is an urgent need for measures and education to identify and treat patients with hepatitis C to eradicate this disease. According to the drug sale statistics from Iran’s ‘Amarnameh’ in 2023, SOF/DCV holds the most significant proportion of the hepatitis C market with an 81% share; however, the SOF/VEL therapeutic regimen is a more cost-effective option.13 Therefore, it is suggested to increase the SOF/VEL sales share for the treatment of hepatitis C. This would not only reduce the total treatment costs of patients but also provide a balanced consumption and optimised decision-making for physicians in the treatment of hepatitis C, which, in this sense, is consistent with the findings of the research conducted 18 18 in Malaysia.

The results of the sensitivity analysis indicate that the model is significantly affected by the changes in CHC state costs. A 20% reduction in CHC state costs would result in a decrease in the projected rise in health sector costs over 5 years, lowering the projected cost from $13.51 million (an 18.84% increase) to $10.52 million (an 18.16% increase). In contrast, if CHC state costs were to increase by 20%, the rise in health sector costs would soar from $13.51 million (an 18.84% increase) to $16.49 million (a 19.31% increase). As the model includes only costs and transition probabilities, PSA focused on these parameters. The narrow CIs around annual treatment costs indicate stable and reliable results despite input uncertainties, reinforcing the robustness of the budget impact estimates even without clinical effectiveness data.

A key limitation of this study is the unavailability of precise, domestically sourced pricing for GLE/PIB, which necessitated the use of estimated retail prices from Turkey. This approximation may affect the accuracy of our cost projections and is a major source of uncertainty. Furthermore, because of data scarcity, our analysis did not account for the costs associated with medication side effects. Consequently, the overall treatment costs may be underestimated, which is a significant consideration for a comprehensive budgetary assessment. In addition, some transition probabilities were derived from international studies rather than local data, which could affect the generalisability of our findings to the specific Iranian context. Finally, although our model’s exclusive focus on costs and transition probabilities limited the analysis to a budget impact perspective, a PSA was conducted to mitigate the effects of these uncertainties, thus supporting the robustness of our estimates.

This post was originally published on https://bmjopen.bmj.com